NCT07175051View on ClinicalTrials.gov

Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

October 31, 2029

Study Completion Date

October 31, 2030

Conditions
Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)Albuminuria
Interventions
DRUG

Empagliflozin (oral)

10 mg

Trial Locations (1)

60302

University of Illinois Chicago, Sickle Cell Center, Chicago

All Listed Sponsors
lead

University of Illinois at Chicago

OTHER